Minireview in AAC has been published

Protein binding: do we ever learn?

Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U.
Antimicrob Agents Chemother. 2011 May 2.

This publication aimed at “getting the in vitro testing right”. It was intended to raise awareness concerning fundamental flaws of in vitro testing to assess the impact of protein binding and the conclusions that are drawn from the results. We published a similar article two years ago that aimed at issues in testing and interpreting tissue concentrations: Tissue concentrations: do we ever learn? (JAC 2008)

Tissue concentrations: do we ever learn?

Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O.
J Antimicrob Chemother. 2008 Feb;61(2):235-7.  Review

Advertisements

EPASG newsletter

Our EPASG (European PK/PD of Anti-Infectives Study Group) newsletter has been sent out to all ESCMID members.

To receive the EPASG newsletter and stay informed about our activities in the PK/PD field log in or register at the ESCMID website, go to “My profile” and tick the box for EPASG (second page of profile).

Our article on PK/PD for old antibiotics has been published

Drug Resist Updat. 2011 Mar 25. [Epub ahead of print]
Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, Macgowan A, Theuretzbacher U, Turnidge J.

Abstract

There is a growing need to optimize the use of old and new antibiotics to treat serious as well as less serious infections. The topic of how to use pharmacokinetic and pharmacodynamic (PK/PD) knowledge to conserve antibiotics for the future was elaborated on in a workshop of the conference (The conference “The Global Need for Effective Antibiotics – moving towards concerted action”, ReAct, Uppsala, Sweden, 2010). The optimization of dosing regimens is accomplished by choosing the dose and schedule that results in the antimicrobial exposure that will achieve the microbiological and clinical outcome desired while simultaneously suppressing emergence of resistance. PK/PD of antimicrobial agents describe how the therapeutic drug effect is dependent on the potency of a drug against a microorganism and the exposure (the concentration of antimicrobial available for effect over time). The description and modeling of these relationships quantitatively then allow for a rational approach to dose optimization and several strategies to that purpose are described. These strategies include not only the dosing regimen itself but also the duration of therapy, preventing collateral damage through inappropriate use and the application of PK/PD in drug development. Furthermore, PK/PD relationships of older antibiotics need to be urgently established. The need for global harmonization of breakpoints is also suggested and would add efficacy to antibiotic therapy. For each of the strategies, a number of priority actions are provided.

Symposium at ECCMID

Don’t miss our symposium at ECCMID!

My proposal for a symposium arranged with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG) and the ISC Working Group: Antimicrobials of the Future has been accepted by ESCMID.
ECCMID 2011
, May, 7-10, 2011, Milano, Italy

Bridging the gap of innovation – what we all could do

* Antibacterial pipelines – what to expect in the future (U. Theuretzbacher)
* Political processes for the global need for effective antibiotics – moving towards concerted action (O. Cars)
* New ways of using old and coming antibiotics (J. Mouton)
* Improving usage by guidelines – the European experience (P. Tulkens)